Lantheus Medical Imaging, Inc. announced that the company has added a Low-Enriched Uranium (LEU) TechneLite(R) (Technetium Tc 99m Generator) generator to the company's nuclear imaging product portfolio. Lantheus' LEU TechneLite(R) generator is the first technetium-99m (Tc-99m) generator in the United States that contains molybdenum-99 (Mo-99) produced from at least 95% LEU. With greater access to LEU Mo-99 through its supply chain diversification strategy, Lantheus can now move closer to its goal of eventually eliminating Highly Enriched Uranium (HEU)-sourced Mo-99 from its supply chain.

With the introduction of the LEU TechneLite(R) generator, Lantheus fully supports the U.S. government's global nuclear security strategy to encourage reliable supplies of medical radioisotopes produced from non-HEU sources. Mo-99 is the parent isotope of Tc-99m, which is the radioisotope most widely used for nuclear imaging tests. Tc-99m is used in approximately 15 million doses in the U.S. annually.(1) As a leader in the radiopharmaceutical business, Lantheus has secured the most globally diversified and balanced Mo-99 supply chain in the industry, and receives the medical isotope from four of the five major processors and seven of the eight associated reactors.